Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.

Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F.

Leuk Res. 2013 Feb;37(2):206-13. doi: 10.1016/j.leukres.2012.10.021. Epub 2012 Nov 22. Review.

PMID:
23177797
2.

In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).

Marfe G, Di Stefano C.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):58-68. Review.

PMID:
19663771
3.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

4.

Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Tolomeo M, Dieli F, Gebbia N, Simoni D.

Anticancer Agents Med Chem. 2009 Oct;9(8):853-63. Review.

PMID:
19538165
5.

Emerging drugs for chronic myeloid leukemia.

Cilloni D, Messa E, Rotolo A, Saglio G.

Expert Opin Emerg Drugs. 2010 Jun;15(2):175-84. doi: 10.1517/14728211003621220. Review.

PMID:
20201747
6.

Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.

Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P.

Leuk Res. 2010 Jan;34(1):123-7. doi: 10.1016/j.leukres.2009.07.009. Epub 2009 Jul 28. Review.

PMID:
19640584
7.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.

PMID:
16213151
8.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.

9.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

10.

[Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].

Nasr R, Bazarbachi A.

Pathol Biol (Paris). 2012 Aug;60(4):239-45. doi: 10.1016/j.patbio.2012.05.010. Epub 2012 Jun 26. Review. French.

PMID:
22743097
11.

Emerging therapies in chronic myeloid leukemia.

Gora-Tybor J.

Curr Cancer Drug Targets. 2012 Jun;12(5):458-70. Review.

PMID:
22483154
12.

Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.

Martin MG, Dipersio JF, Uy GL.

Leuk Lymphoma. 2009 Jan;50(1):14-23. doi: 10.1080/10428190802517765. Review.

PMID:
19117213
13.

Curing chronic myeloid leukemia.

Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX.

Curr Hematol Malig Rep. 2012 Jun;7(2):103-8. doi: 10.1007/s11899-012-0117-2. Review.

PMID:
22410764
14.

Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.

Jiang Q, Wang HB, Yu L, Gale RP.

J Cancer Res Clin Oncol. 2017 Jun;143(6):1013-1022. doi: 10.1007/s00432-017-2353-2. Epub 2017 Mar 1.

PMID:
28251350
15.

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS.

Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016. Review.

PMID:
20537386
16.

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H.

IDrugs. 2007 Jul;10(7):468-79.

PMID:
17642017
17.

The expanding role of nilotinib in chronic myeloid leukemia.

Kim TD, le Coutre P.

Expert Opin Drug Saf. 2011 Jan;10(1):97-107. doi: 10.1517/14740338.2011.532486. Epub 2010 Dec 2. Review.

PMID:
21121868
18.

Systematic assessment of decision-analytic models for chronic myeloid leukemia.

Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U.

Appl Health Econ Health Policy. 2014 Apr;12(2):103-15. doi: 10.1007/s40258-013-0071-8. Review.

PMID:
24385259
19.

The second generation of BCR-ABL tyrosine kinase inhibitors.

Tauchi T, Ohyashiki K.

Int J Hematol. 2006 May;83(4):294-300. Review.

PMID:
16757427
20.

BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.

Leonetti F, Stefanachi A, Nicolotti O, Catto M, Pisani L, Cellamare S, Carotti A.

Curr Med Chem. 2011;18(19):2943-59. Review.

PMID:
21651486

Supplemental Content

Support Center